A phase 1 study of lucar-G39D: A novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cells in adults with relapsed / refractory B-cell non-Hodgkin lymphoma (NHL)

Jingwei Yu(Tianjin Medical University Cancer Institute and Hospital), Huilai Zhang(Shanxi Medical University), Kaiyang Ding(Anhui Provincial Hospital), Yongxin Luo(Viva Biotech (China)), Yinrui Jiang(Viva Biotech (China)), Dandan Fan(Zhejiang Lab), Xiaoyu Feng(Viva Biotech (China)), Lemei Jia(Tsinghua University), Ning Chen(Xinjiang Academy of Agricultural and Reclamation Science), Linlin Cao(University of Science and Technology of China), Qi Zhou(Viva Biotech (China)), Zhengzi Qian(Tianjin Medical University Cancer Institute and Hospital), Liping Sun(Yangzhou University), Nan Wang(Shanghai First People's Hospital), Wenjie Wang(Harbin Medical University), Jing Liu(Wuhan University), Pu Wang(Shandong University), Jian Li(Shanghai Medical Information Center), Yafeng Zhang, Xianming Liu(Qingdao University), Qing Dai(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Ming(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiayi Han(Second Affiliated Hospital of Xi'an Jiaotong University), Lanfang Li(China-Japan Friendship Hospital), Da Xu(Viva Biotech (China)), Cong Feng(Nanjing University of Science and Technology), Yue Zhu(China Pharmaceutical University), Lihua Qiu(Tianjin Medical University Cancer Institute and Hospital)
Blood
November 3, 2025
Cited by 0


Related Papers